REG - Allergy Therapeutics - Result of Annual General Meeting

Allergy TherapeuticsAnnouncement

16/12/2024 15:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241216:nRSP2798Qa&default-theme=true

RNS Number : 2798Q  Allergy Therapeutics PLC  16 December 2024

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

 

Result of Annual General Meeting

 

 

16 December 2024 Allergy Therapeutics plc (AIM:AGY), the fully integrated
specialty pharmaceutical group specialising in allergy vaccines, announces
that all resolutions proposed at the 2024 Annual General Meeting ("AGM") held
today were duly passed by shareholders on a show of hands.

 

Resolutions 1 to 13 (inclusive) were proposed as ordinary resolutions and
resolutions 14 to 16 (inclusive) were proposed as special resolutions. The
results of the proxy votes received ahead of the meeting are outlined in the
table below.

 

 

 Resolution                                                                      For:            %age   Against:    %age  Total Votes Cast  % of ISC  Withheld
 1. Approval of 2024 Accounts                                                    4,452,448,269   99.99  3,624       0.01  4,452,453,003     93.41     1,110

 2. Approval of Directors'                                                       4,451,072,636   99.97  1,379,257   0.03  4,452,453,003     93.41     1,110

 Remuneration Report
 3. Approval of Directors'                                                       4,438,375,536   99.68  14,075,557  0.32  4,452,453,003     93.41     1,910

 Remuneration Policy
 4. To elect Dr. Shaun Furlong as a Director                                                     99.99  33,283      0.01  4,452,453,003     93.41     2,007,147

                                                                                 4,450,412,573

 5. To elect David Ball as a Director                                            4,450,411,773   99.99  33,283      0.01  4,452,453,003     93.41     2,007,947

 6. To re-elect Anthony Parker as a Director                                     4,436,433,902   99.69  14,011,154  0.31  4,452,453,003     93.41     2,007,947

 7. To re-elect Zheqing (Simon) Shen as a Director                               4,436,433,902   99.69  14,011,154  0.31  4,452,453,003     93.41     2,007,947

 8. To re-elect Peter Jensen O.B.E. as a Director                                4,436,433,902   99.69  14,011,154  0.31  4,452,453,003     93.41     2,007,947

 9. To re-appoint BDO LLP as auditors of the Company                             4,451,995,528   99.99  3,624       0.01  4,452,453,003     93.41     453,851

 10. To authorise the Directors to agree the Auditors remuneration               4,452,434,231   99.99  11,625      0.01  4,452,453,003     93.41     7,147

 11. To approve the form of contract and authorise the off-market purchase of    4,452,433,431   99.99  11,625      0.01  4,452,453,003     93.41     7,947
 deferred shares

 12. To authorise the Directors to finalise and implement arrangements for the   4,436,556,360   99.69  13,895,533  0.31  4,452,453,003     93.41     2,001,110
 grant of the special, out of cycle, long term incentive awards to the

 Company's senior executive team and additional option awards to the Company's
 employees.
 13. To authorise the Directors to allot the unissued share capital up to a      4,452,337,990   99.99  15,655      0.01  4,452,453,003     93.41     99,358
 specific amount (s.551)

 14. Special Resolution: To authorise the Directors to allot equity securities   4,438,461,319   99.69  13,892,326  0.31  4,452,453,003     93.41     99,358
 for cash without first being required to offer such shares to existing

 shareholders for a period expiring at the conclusion of the next annual
 general meeting of the Company or 16 March 2026, whichever occurs first.
 15. Special Resolution: To authorise the Directors to allot equity securities   4,438,461,319   99.69  13,892,326  0.31  4,452,453,003     93.41     99,358
 and/or sell treasury shares for cash without first being required to offer

 such securities to existing shareholders.
 16. Special Resolution: To amend the Articles of Association.                   4,450,427,300   99.99  17,756      0.01  4,452,453,003     93.41     2,007,947

 

 

 

- ENDS -

 

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker / Rory Sale

Nigel Birks - Life Science Specialist Sales

Tamar Cranford Smith - Sales

+44 (0)20 7220 0500

 

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@icrhealthcare.com
(mailto:allergytherapeutics@icrhealthcare.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third-party
products from its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. Its broad pipeline of
products in clinical development includes vaccines for grass, tree, house dust
mite and peanut. For more information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGFFUFIMELSEEE